**Referral Form for Isotretinoin Treatment (UHS)**

Before referring a patient with acne vulgaris for the consideration of isotretinoin please ensure that you consider ALL elements of the sections below and that evidence of this is provided in your referral to prevent the referral being returned.

|  |  |  |  |
| --- | --- | --- | --- |
| **SECTION A - Treatment of acne vulgaris in past 2 years** | | | |
|  | | Yes | No |
| 1. have at least moderate to severe acne according to the NICE guideline definition above | |  |  |
|  | | | |
| (b) Acne has failed to improve despite two 12 week courses of different oral antibiotics from the list below in combination with a topical treatment (fixed combination of topical adapalene with benzoyl peroxide (e.g. Epiduo) or topical azelaic acid (e.g. Finacea or Skinoren)? | |  |  |
|  | Lymecycline 408mg daily |  |  |
| Doxycycline 100mg daily |  |  |
| Erythromycin 500mg twice daily |  |  |
| Trimethoprim 200mg or 300mg twice daily |  |  |
| **Optional Comments (Please add any commentary you feel may benefit the referral)** | | | |
| *Further information on the treatment pathway for patients with acne can be found here*  [Recommendations | Acne vulgaris: management | Guidance | NICE](https://www.nice.org.uk/guidance/ng198/chapter/Recommendations#managing-acne-vulgaris) | | | |
| *If “yes” is ticked for (a) and (b) above, move to section B.* | | | |
| **SECTION B- Mental health history** | | | |
| *Isotretinoin has rarely been associated with the development of mood disturbance, anxiety, depression and suicidal disturbance (BNF)* | | | |
|  | | Yes | No |
| Has the patient been counselled about the risk of possible psychiatric side effects with isotretinoin?  *MHRA advise discussion before referral* (r*eferral will be accepted if not completed)* | |  |  |
| Does the patient have a history of mental illness?  If yes, please describe below: | |  |  |
| Comment: | | | |
| Do you have any current concerns regarding the patient’s mental health?  If yes, please describe below: | |  |  |
| Comment: | | | |
| If the patient’s current mental health status is felt to be safe to commence Isotretinoin please move to section C. | | | |
|  | | | |
| **SECTION C** | | | |
| *An EU-wide review has concluded that on rare occasions, oral isotretinoin, indicated for severe acne, may cause sexual side-effects, including erectile dysfunction and decreased libido (BNF)* | | | |
|  | | Yes | No |
| Has the patient been counselled about the possible risk of sexual dysfunction with isotretinoin?  *MHRA advise discussion before referral* (r*eferral will be accepted if not completed)* | |  |  |
| **Contraception (female patients / patients with a uterus)** | | | |
| Is the patient currently on contraception and planning willing to remain on this until review and whilst on a course of isotretinoin and for 5 weeks afterwards? | |  |  |
| If the answer to the above question is “no” please strongly consider starting the patient on a suitable contraceptive that they would be willing to remain on until 5 weeks following a course of isotretinoin | | | |